Profound Medical (PRN.TO) Osake Kurssi

Profound Medical Corp is primarily active in the medical industry.

The main competitors of Profound Medical Corp in the market include SonaCare Medical, Inc., EDAP TMS S.A., and Exact Imaging Inc.

Profound Medical Corp is a prominent medical technology company that focuses on developing and commercializing innovative treatments for prostate cancer. Established in 2008, Profound Medical has made significant strides in the field of image-guided therapy. Their flagship product, TULSA-PRO, utilizes MRI and ultrasound technology to deliver precise and personalized thermal ablation treatments, effectively destroying targeted prostate tissue while minimizing damage to surrounding areas. This revolutionary approach provides patients with a non-invasive or minimally invasive option, reducing side effects and improving outcomes. Profound Medical Corp continues to advance the field of prostate cancer treatment, offering hope to patients worldwide.

Profound Medical Corp, a leading medical device company, has achieved several significant milestones. Firstly, they received FDA approval for their revolutionary TULSA-PRO system, which offers non-invasive treatment for prostate cancer. This milestone has positioned Profound Medical Corp as a game-changer in the field of prostate cancer treatments. Additionally, the company successfully completed a clinical trial, showcasing the TULSA-PRO system's remarkable efficacy and safety profile. Furthermore, Profound Medical Corp expanded its market reach by establishing strategic partnerships with renowned cancer centers and leading healthcare providers. Through continuous innovation and collaboration, Profound Medical Corp has cemented its position as a trailblazer in the fight against prostate cancer.

Profound Medical Corp primarily operates in the United States, Canada, and Europe.

Profound Medical Corp is committed to transforming the lives of patients with minimally invasive, incision-free therapies for the treatment of prostate disease. Their corporate philosophy revolves around innovation, patient-centricity, and a dedication to advancing medical technologies. By leveraging their cutting-edge TULSA-PRO® system, Profound Medical Corp aims to provide precise and personalized treatments, reducing potential side effects while enhancing treatment outcomes. With a focus on research and development, they strive to continuously improve their therapeutic offerings and expand their reach globally. Profound Medical Corp's values encompass integrity, collaboration, and a commitment to revolutionizing healthcare through their transformative solutions.

Analyytikot asettavat tällä hetkellä Profound Medical-osakkeelle keskimääräisen tavoitehinnan 10,91 USD (mediaani: 10,91 USD), mikä merkitsee +56,8 % viimeisimpään hintaan verrattuna. Konsensus perustuu 5 analyytikkoarvioon.

Profound Medical Analyytikkojen kursstavoitteet 2026

5 analyytikkoa arvioi tällä hetkellä Profound Medical-osaketta: 4 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Profound Medical-yhtiöltä 25,80 M USD liikevaihtoa ja −0,66 USD osakekohtaista tulosta.

Profound Medical Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Profound Medical-osake noteerataan hintaan 6,33 EUR (7,07 USD).

Profound Medical-osake (PRN.TO) on listattuna 2 pörssissä, muun muassa: NASDAQ (PROF), Toronto (PRN.TO).

Profound Medical Corp is a leading company in the development of innovative medical technologies for the treatment of prostate cancer. The company's business model is based on the development and marketing of its advanced therapy systems for the treatment of localized prostate cancer. The divisions of Profound Medical Corp include research and development, marketing and distribution of medical devices. The company focuses on developing medical products that meet the patients' need for state-of-the-art, minimally invasive treatments. The devices of Profound Medical Corp are targeted towards the target group of urologists and radiation therapists. The main product of Profound Medical Corp is the TULSA-PRO® System, an innovative HIFU (High-Intensity Focused Ultrasound) system that enables the minimally invasive treatment of localized prostate cancer. The technology is based on an ultrasound device that destroys the diseased tissue in the prostate using sound waves without damaging the surrounding tissue. The minimally invasive procedure is performed on an outpatient basis and minimizes the risk of complications and side effects. The TULSA-PRO® System offers many advantages compared to other conventional treatment methods. For example, it is gentler and faster than radiation therapy or surgery and has a better success rate than the use of chemotherapy or hormonal therapies. In addition, the TULSA-PRO® System is approved by the FDA, the American Food and Drug Administration, and CE-marked. The company also provides comprehensive training and technical support for users of the TULSA-PRO® System. Therefore, consulting, device management, and continuous maintenance are further services offered by Profound Medical Corp. In the course of its business activities, the company strives for close cooperation with leading research institutions and specialists in the field of cancer treatment. The goal is to develop innovative technologies that improve the diagnosis and treatment of prostate cancer and increase the quality of life of affected patients. In conclusion, the business model of Profound Medical Corp is focused on the needs of patients and their doctors. With the development and marketing of innovative medical devices, the company offers advanced technology that enables minimally invasive treatment of prostate cancer. Through collaboration with leading research institutions, Profound Medical Corp further expands its expertise in the field of cancer treatment.

odotettu liikevaihto Profound Medical on 25,80 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Profound Medical on −20,42 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Profound Medical:n hinta-voitto-suhde (P/E) on tällä hetkellä −10,64. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Profound Medical-osakkeen arvostusta.

Profound Medical:n hinta-myynti-suhde (P/S) on tällä hetkellä 8,42. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Profound Medical-osakkeen arvostuskennuslukuna.

Profound Medical:n Eulpool-laatuscore on 3/10.

Profound Medical:n ISIN on CA74319B5027. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Profound Medical:n ticker on PRN.TO. Tämä pörssinoteeraus käytetään Profound Medical-osakkeiden kauppaan pörssissä.